




Shelby Kelsh, PharmD; Hanna Brock, PharmD Candidate  
 Ferris State University College of Pharmacy, Grand Rapids, MI

INTRODUCTION

- GLP-1 agonist use has been associated with gastrointestinal upset, retinopathy and gallstones.
- This research aims to compare the glucose lowering effects and side effect profiles of semaglutide and dulaglutide when used in patients with diabetes.

METHODS

- Retrospective cohort study that included patients newly prescribed semaglutide or dulaglutide and at least one other antidiabetic medication 2018 - 2021.
- Patients were propensity-matched based on baseline HbA1c, BMI, age, gender, race and insulin use.



KEY FINDINGS

Variable	Pre-Match		Matched Data	
	Dulaglutide	Semaglutide	Dulaglutide	Semaglutide
	73.2%	26.8%	50%	50%
Race: White	85.3%	84.0%	83.7%	84.0%
Ethnicity: Hispanic	7.8%	9.8%	8.8%	9.8%
Male	54.1%	54.3%	54.9%	54.3%
BMI*	35.3	36.2	35.8	36.2
Age*	61.0	57.0	57.0	57.0
Insulin Use*	28.1%	35.9%	36.4%	35.9%
Number of DM Meds				
0	20.9%	19.8%	19.3%	19.8%
1	47.7%	53.3%	52.4%	53.3%
2	25.2%	22.2%	23.0%	22.2%
≥3	6.3%	4.7%	5.5%	4.7%
*p<0.05				

Variable	Pre Match	Matched Data	
	Total (N=5541)	Dulaglutide (N=783)	Semaglutide (N=783)
GI Event	19.3%	23.9%	24.9%
Gall Stones	2.6%	3.4%	2.4%
Time to Gall Stones (Days)	239.8	336.8	236.8
Pancreatitis	0.8%	0.5%	0.9%
Time to Pancreatitis (Days)	180.3	445.3	210.8
Retinopathy	9.2%	10.7%	9.3%

RESULTS

Variable	Pre Match	Matched Data	
	Total (N=5541)	Dulaglutide (N=783)	Semaglutide (N=783)
CV Event	788 (14.2%)	128 (16.3%)	111 (14.2%)
Myocardial Infarction	137 (2.5%)	26 (3.3%)	17 (2.2%)
Unstable Angina	57 (1.0%)	9 (1.1%)	10 (1.3%)
Coronary Revascularization	38 (0.7%)	4 (0.5%)	9 (1.1%)
Stroke/TIA	216 (3.9%)	34 (4.3%)	34 (4.4%)
Peripheral Artery Disease	526 (9.5%)	88 (11.2%)	71 (9.1%)

CONCLUSIONS

- Both semaglutide and dulaglutide resulted in similar HbA1c reductions, but more weight loss was seen with semaglutide and more ADRs were seen with dulaglutide.
- Larger, long-term trials are necessary to determine the clinical significance of these findings.

REFERENCES AND DISCLOSURES

1. Ferdinand, K. C., Botros, F. T., Atisso, C. M., & Sager, P. T. (2016, February 24). Cardiovascular safety for once-weekly dulaglutide in type 2 diabetes: A pre-specified meta-analysis of prospectively adjudicated cardiovascular events - cardiovascular diabetes. SpringerLink. <https://link.springer.com/article/10.1186/s12933-016-0355-z/tables/5>
2. Goldman, J. (n.d.). Cardiovascular Safety Outcomes of once-weekly GLP-1 receptor agonists in people with type 2 diabetes - goldman - 2020 - journal of clinical pharmacy and Therapeutics - Wiley Online Library. Wiley Online Library. <https://onlinelibrary.wiley.com/doi/10.1111/jcpt.13226>
3. Marso, S., & Bain, S. (2016, November 10). SEMAGLUTIDE and cardiovascular outcomes in patients with type 2 diabetes | New England Journal of Medicine. The New England Journal of Medicine. <https://www.nejm.org/doi/full/10.1056/NEJMoa1607141>

These authors have declared no potential conflicts of interest.  
 Contact information: Hanna Brock – hbrock@ferris.edu